Spots Global Cancer Trial Database for Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
Official Title: Phase II Study on Letrozole in Patients With Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
Study ID: NCT00171808
Conditions
Interventions
Study Description
Brief Summary: In Western industrialized countries, endometrial cancer is the most common malignancy of the female reproductive tract. The general therapy options are surgery, radiotherapy, chemotherapy and endocrine therapy. This trial will investigate the efficacy and safety of letrozole in the treatment of advanced or recurrent hormone receptor-positive endometrial cancer .
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Ebersberg, Germany, Celle, , Germany
Heidelberg, Germany, Ebersberg, , Germany
Novartis Investigative Site, Freiburg, , Germany
Ebersberg, Germany, Hamburg, , Germany
Novartis Investigative Site, Hamburg, , Germany
Celle, Germany, Hannover, , Germany
Tuebingen, Germany, Heidelberg, , Germany
Novartis Investigative Site, Karlsruhe, , Germany
Muenchen, Germany, Kiel, , Germany
Muenchen, Germany, Muenchen, , Germany
Novartis Investigative Site, Muenchen, , Germany
Novartis Investigative Site, Oberaudorf, , Germany
Novartis Investigative Site, Rostock, , Germany
Novartis Investigative Site, Tuebingen, , Germany
Hannover, Germany, Wolfsburg, , Germany
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmeceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
